Finance

Beta
Ask
Lists
PTGX:NASDAQ
Protagonist Therapeutics Inc
$115.03
+1.92%
(+2.17) 1D
$115.03
0.00% (0.00)
Pre-market
Closed: Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTGX...
Open
$113.24
High
$116.57
Low
$113.24
Mkt. cap
7.40B
Avg. vol.
610.06K
Volume
254.00
52-wk high
$116.57
52-wk low
$49.39
EPS
-$1.80
Beta
1.85
Shares outstanding
64.31M
No. of employees
131
Open
$113.24
High
$116.57
Low
$113.24
Mkt. cap
7.40B
Avg. vol.
610.06K
Volume
254.00
52-wk high
$116.57
52-wk low
$49.39
EPS
-$1.80
Beta
1.85
Shares outstanding
64.31M
No. of employees
131
News stories
From sources across the web
About Protagonist Therapeutics Inc
CEO-
Employees131
Founded2006
HeadquartersNewark, California, United States
SectorBiotechnology
Websiteprotagonist-inc.com
Analyst Ratings
Based on 10 analysts giving stock ratings to PTGX in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for PTGX in the last 3 months.
Highest
Current $115.03
$137.00 (+19.10%)
Average
$117.78 (+2.39%)
Lowest
$100.00 (-13.07%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
06/22/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$110.00
-4.4%
06/10/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$113.00
-1.8%
05/13/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$117.00
+1.7%
05/11/2026
Geoff Meacham
Citi
Buy
Maintained
$130.00
+13%
05/10/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$137.00
+19.1%
05/06/2026
Yun Zhong
Wedbush
Buy
Reiterated
$118.00
+2.6%
05/06/2026
Etzer Darout
Barclays
Buy
Maintained
$119.00
+3.5%
05/06/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$100.00
-13.1%
05/05/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$116.00
+0.8%
04/06/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$110.00
-4.4%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.55M
4.71M
7.44M
56.37M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
37.04M
40.00M
46.36M
46.74M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.55M
11.13M
11.43M
13.28M
Operating expense
47.59M
51.13M
57.79M
60.02M
Total operating expenses
47.59M
51.13M
57.79M
60.02M
Operating income
-42.04M
-46.42M
-50.36M
-3.65M
Other non operating income
-
-
27.00K
53.00K
EBT including unusual items
-34.60M
-39.34M
-43.72M
2.28M
EBT excluding unusual items
-34.60M
-39.34M
-43.72M
2.28M
Income tax expense
172.00K
-
666.00K
-1.50M
Effective tax rate
-0.50%
-
-1.52%
-65.85%
Other operating expenses
-
-
-
-
Net income
-34.77M
-39.34M
-44.38M
3.78M
Net profit margin
-626.96%
-834.87%
-596.80%
6.71%
Earnings per share
-0.55
-0.62
-0.69
0.05
Interest and investment income
7.41M
7.05M
6.76M
5.88M
Interest expense
-
-
-
-
Net interest expenses
7.41M
7.05M
6.76M
5.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.74M
-46.06M
-49.98M
-3.24M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer